Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Amortization of Deferred Charges (2023 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Amortization of Deferred Charges over the past 3 years, most recently at $6.8 million for Q2 2025.

  • Quarterly results put Amortization of Deferred Charges at $6.8 million for Q2 2025, up 12.68% from a year ago — trailing twelve months through May 2025 was $20.2 million (up 31.12% YoY), and the annual figure for FY2025 was $20.2 million, up 31.12%.
  • Amortization of Deferred Charges for Q2 2025 was $6.8 million at Lifecore Biomedical, Inc. \De\, up from $4.6 million in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for LFCR hit a ceiling of $8.9 million in Q1 2024 and a floor of -$2.5 million in Q4 2023.
  • Median Amortization of Deferred Charges over the past 3 years was $4.7 million (2024), compared with a mean of $4.5 million.
  • Biggest five-year swings in Amortization of Deferred Charges: surged 263.42% in 2024 and later plummeted 47.9% in 2025.
  • Lifecore Biomedical, Inc. \De\'s Amortization of Deferred Charges stood at -$2.5 million in 2023, then surged by 263.42% to $4.1 million in 2024, then skyrocketed by 65.95% to $6.8 million in 2025.
  • The last three reported values for Amortization of Deferred Charges were $6.8 million (Q2 2025), $4.6 million (Q1 2025), and $4.1 million (Q4 2024) per Business Quant data.